About this trial

The aim of the SAID study is to create a national resource in Sweden to enable comprehensive immunological analyses of an extremely complex and clinically challenging group of individuals with variable forms of immune system dysregulation. We hope to establish a biobank of primarily blood and fecal samples from children and adults, with confirmed or suspected immune dysregulation, as well as age- and sex- matched healthy controls, for comparisons of immune cell/mediator alongside various clinical presentations of these immunological diseases as well as microbiome samples as possible a possible modifier of clinical presentations. The project will also include the establishment of a national database with deep immunological data, treatment and clinical outcomes for these patients, accessible to participating researchers and clinicians.

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Immunomodulation

Treatment groups

500 Participants
are divided into 2 treatment groups

Locations

1
Karolinska InstitutetSE171 77, Stockholm Sweden

Sponsors and collaborators

Karolinska Institutet

Lead sponsor

Karolinska University Hospital

Collaborator

Skane University Hospital

Collaborator

Sahlgrenska University Hospital

Collaborator

Uppsala University Hospital

Collaborator

Region Halland

Collaborator

Region Jönköping County

Collaborator